- Home
- AUPH vs CRTO Comparison
AUPH vs CRTO Comparison
Compare AUPH & CRTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- CRTO
- Stock Information
- Founded
- AUPH 1993
- CRTO 2005
- Country
- AUPH Canada
- CRTO France
- Employees
- AUPH N/A
- CRTO N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- CRTO Advertising
- Sector
- AUPH Health Care
- CRTO Consumer Discretionary
- Exchange
- AUPH Nasdaq
- CRTO Nasdaq
- Market Cap
- AUPH 1.4B
- CRTO 1.2B
- IPO Year
- AUPH 1999
- CRTO 2013
- Fundamental
- Price
- AUPH $12.83
- CRTO $22.10
- Analyst Decision
- AUPH Strong Buy
- CRTO Buy
- Analyst Count
- AUPH 3
- CRTO 9
- Target Price
- AUPH $12.00
- CRTO $39.11
- AVG Volume (30 Days)
- AUPH 1.5M
- CRTO 296.7K
- Earning Date
- AUPH 11-06-2025
- CRTO 10-29-2025
- Dividend Yield
- AUPH N/A
- CRTO N/A
- EPS Growth
- AUPH N/A
- CRTO 44.35
- EPS
- AUPH 0.42
- CRTO 2.38
- Revenue
- AUPH $260,111,000.00
- CRTO $1,946,032,000.00
- Revenue This Year
- AUPH $16.92
- CRTO N/A
- Revenue Next Year
- AUPH $14.43
- CRTO $2.19
- P/E Ratio
- AUPH $29.12
- CRTO $9.43
- Revenue Growth
- AUPH 25.59
- CRTO N/A
- 52 Week Low
- AUPH $6.55
- CRTO $21.44
- 52 Week High
- AUPH $12.90
- CRTO $47.27
- Technical
- Relative Strength Index (RSI)
- AUPH 63.83
- CRTO 39.64
- Support Level
- AUPH $12.18
- CRTO $21.44
- Resistance Level
- AUPH $12.90
- CRTO $23.06
- Average True Range (ATR)
- AUPH 0.42
- CRTO 0.74
- MACD
- AUPH -0.06
- CRTO -0.13
- Stochastic Oscillator
- AUPH 92.89
- CRTO 18.55
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.